Publication: SEOM-TTCC clinical guideline in nasopharynx cancer (2021).
Loading...
Identifiers
Date
2022-03-18
Authors
Rueda-Dominguez, Antonio
Cirauqui, Beatriz
Garcia-Castaño, Almudena
Alvarez-Cabellos, Ruth
Carral-Maseda, Alberto
Castelo-Fernandez, Beatriz
Iglesias-Rey, Leticia
Rubio-Casadevall, Jordi
Arrazubi, Virginia
Mesia, Ricard
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Metrics
Export
Abstract
Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiotherapy (RT) is the cornerstone of locoregional treatment of non-disseminated disease and the association of chemotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy and patients may achieve a long survival time.
Description
MeSH Terms
Humans
Nasopharyngeal Carcinoma
Nasopharyngeal Neoplasms
Nasopharyngeal Carcinoma
Nasopharyngeal Neoplasms
DeCS Terms
Quimioterapia
Gemcitabina
Carcinoma Nasofaríngeo
Epidemiología
Radioterapia
Histología
Gemcitabina
Carcinoma Nasofaríngeo
Epidemiología
Radioterapia
Histología
CIE Terms
Keywords
Clinical Practice Guidelines, Diagnosis, Follow-up, Nasopharyngeal cancer, Treatment
Citation
Rueda Domínguez A, Cirauqui B, García Castaño A, Alvarez Cabellos R, Carral Maseda A, Castelo Fernández B, et al. SEOM-TTCC clinical guideline in nasopharynx cancer (2021). Clin Transl Oncol. 2022 Apr;24(4):670-680